Baricitinib
Baricitinib
Baricitinib (pronounced as baa-ri-si-ti-nib) is a medication used for the treatment of rheumatoid arthritis and COVID-19. It is an Janus kinase inhibitor that interferes with the JAK-STAT signaling pathway, a type of protein coding communication process that transmits information from chemical signals outside the cell, through the cell membrane, and into gene promoters on the DNA in the cell nucleus.
Etymology
The name "Baricitinib" is derived from the class of drugs it belongs to, known as Janus kinase inhibitors. The "bari" part of the name is a prefix used in pharmacology to denote drugs that inhibit the Janus kinase family of enzymes. The "citinib" suffix is common among kinase inhibitors.
Usage
Baricitinib is used primarily for the treatment of moderate to severe rheumatoid arthritis in adults who have not responded well to one or more tumor necrosis factor (TNF) antagonist therapies. It is also used in combination with remdesivir in the treatment of COVID-19.
Related Terms
- Janus kinase inhibitor
- Rheumatoid arthritis
- COVID-19
- JAK-STAT signaling pathway
- Tumor necrosis factor (TNF) antagonist
- Remdesivir
See Also
- List of Janus kinase inhibitors
- List of medications for rheumatoid arthritis
- List of medications for COVID-19
External links
- Medical encyclopedia article on Baricitinib
- Wikipedia's article - Baricitinib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski